MX2022011958A - Conjugados de anticuerpo degradador y métodos de uso de los mismos. - Google Patents

Conjugados de anticuerpo degradador y métodos de uso de los mismos.

Info

Publication number
MX2022011958A
MX2022011958A MX2022011958A MX2022011958A MX2022011958A MX 2022011958 A MX2022011958 A MX 2022011958A MX 2022011958 A MX2022011958 A MX 2022011958A MX 2022011958 A MX2022011958 A MX 2022011958A MX 2022011958 A MX2022011958 A MX 2022011958A
Authority
MX
Mexico
Prior art keywords
degrader
methods
antibody conjugates
same
binding group
Prior art date
Application number
MX2022011958A
Other languages
English (en)
Inventor
Edward Ha
Paul A Jaminet
Shou-Ching S Jaminet
Manish S Hudlikar
Gabriel Gonzalez
Original Assignee
Angiex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiex Inc filed Critical Angiex Inc
Publication of MX2022011958A publication Critical patent/MX2022011958A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen conjugados de anticuerpo-degradador (DAC), que comprenden anticuerpos anti TM4SF1 y fragmentos de unión a antígeno de los mismos. Las moléculas degradadoras tal como se describen comprenden un grupo de unión a ubiquitina ligasa E3 (E3LB) y un grupo de unión a proteína (PB). Pueden utilizarse enlazadores entre los anticuerpos y las moléculas degradadoras (L1) y entre el grupo de unión a ubiquitina ligasa E3 (E3LB) y el grupo de unión a proteínas (PB) de la molécula degradadora (L2). También se describen métodos de uso de dichos DAC.
MX2022011958A 2020-03-27 2021-03-26 Conjugados de anticuerpo degradador y métodos de uso de los mismos. MX2022011958A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000991P 2020-03-27 2020-03-27
US202063044699P 2020-06-26 2020-06-26
PCT/US2021/024535 WO2021195598A2 (en) 2020-03-27 2021-03-26 Degrader-antibody conjugates and methods of using same

Publications (1)

Publication Number Publication Date
MX2022011958A true MX2022011958A (es) 2023-01-11

Family

ID=77890749

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011958A MX2022011958A (es) 2020-03-27 2021-03-26 Conjugados de anticuerpo degradador y métodos de uso de los mismos.

Country Status (8)

Country Link
US (1) US20230126271A1 (es)
EP (1) EP4126042A2 (es)
JP (1) JP2023520371A (es)
CN (1) CN115734789A (es)
AU (1) AU2021244621A1 (es)
CA (1) CA3172516A1 (es)
MX (1) MX2022011958A (es)
WO (1) WO2021195598A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11535607B2 (en) 2018-04-20 2022-12-27 Valo Health, Inc. Isoindolines as HDAC inhibitors
WO2023056069A1 (en) * 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024006252A1 (en) * 2022-06-28 2024-01-04 The Regents Of The University Of Colorado, A Body Corporate Dual inhibition of mdm2 and eif2-alpha induces cell death in multiple cancer cell types

Also Published As

Publication number Publication date
WO2021195598A2 (en) 2021-09-30
EP4126042A2 (en) 2023-02-08
CN115734789A (zh) 2023-03-03
WO2021195598A3 (en) 2021-12-16
AU2021244621A1 (en) 2022-10-20
JP2023520371A (ja) 2023-05-17
US20230126271A1 (en) 2023-04-27
CA3172516A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
MX2022011958A (es) Conjugados de anticuerpo degradador y métodos de uso de los mismos.
CY1119416T1 (el) Αντισωματα εναντι των τοξινων toy clostridium difficile (κλωστηριδιο το δυσκολο) και χρησεις εξ' αυτων
WO2021163064A3 (en) Antibodies and fusion proteins that bind to ccr8 and uses thereof
NO20083053L (no) Humane monoklonale antistoffer mot O8E
WO2006089230A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
WO2019241430A3 (en) Antibody-oligonucleotide conjugates
TNSN08255A1 (en) Anti-mn antibodies and methods of using same
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
WO2007116360A3 (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
MX2022015847A (es) Proteinas de union a cd123 y composiciones y metodos relacionados.
MX2021011997A (es) Enlazadores de conjugacion mejorados.
DK1692158T3 (da) VEGF-binding og understøttede peptider til behandling af hudsygdomme
WO2006068975A3 (en) Binding proteins specific for human matriptase
MY194997A (en) Anti-ccr7 antibody drug conjugates
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
WO2008098917A3 (en) Novel antibodies against igf-ir
WO2008085878A3 (en) High affinity antibodies that neutralize staphylcoccus enterotoxin b
AU2019433019A8 (en) Antibodies binding CD40 and uses thereof
EP4253959A3 (en) Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
ZA202201464B (en) Anti-tigit antibodies and application thereof
MX2021010254A (es) Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos.
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
WO2004052932A3 (en) Antibody (“11c7”) anti nogo a and its pharmaceutical use
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.